Pharma & Biotech 2016 Preview

Despite the recent downturn in investor sentiment in the pharma and biotech sectors, 2016 is set to see the sector’s research and development productivity continue to grow with new drug launches and a limited impact of patent expiries.

According to EP Vantage’s new report, Pharma & Biotech 2016 Preview, 2016 will see:

The launch of 12 blockbusters

Pfizer overtake Novartis to be industry’s biggest company by sales - even without Allergan

AstraZenca slip to the bottom of the top 10 biggest companies league table

Humira to remain industry’s biggest selling drug

Older therapies such as oncolytic viruses and vaccines that have so far disappointed as monotherapies might benefit from the combination approach

AbbVie and AstraZeneca become the companies facing the biggest patent risks in 2016

报告下载：

生物制药2016